Alfuzosin (10 mg) Does Not Affect Blood Pressure in Young Healthy Men

European Urology

Volumn 50, Issue 6, 2006, Pages 1292-1298

  Mondaini, Nicola ^a   Giubilei, Gianluca ^a   Ungar, Andrea ^a   Gontero, Paolo ^b   Cai, Tommaso ^a   Gavazzi, Andrea ^a   Bartoletti, Riccardo ^a   Geppetti, Pierangelo ^a   Carini, Marco ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

1 adrenoceptor antagonist; Alfuzosin; BPH; Distal ureteral stones; Prostatitis; Young healthy volunteers

Indexed keywords

ALFUZOSIN; PLACEBO;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; HEART RATE; HUMAN; HYPOTENSION; LIGHT DARK CYCLE; MALE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SELF EXAMINATION; SYSTOLIC BLOOD PRESSURE;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; BLOOD PRESSURE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HEART RATE; HUMANS; MALE; PROGNOSIS; PROSTATITIS; QUINAZOLINES; REFERENCE VALUES; URETERAL CALCULI;

EID: 33750609502     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.06.016     Document Type: Article

References (23)

1. Lowe F.C. Role of the newer alpha1-adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin Ther 26 (2004) 1701-1713
2. Hofner K., and Jonas U. Alfuzosin: a clinically uroselective alpha1-blocker. World J Urol 19 (2002) 405-412
3. Anderson K.E. The concept of uroselectivity. Eur Urol 33 (1998) 7-11
4. Van Kerrebroeck P., Jardin A., Laval K.U., and Van Cangh P. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. Eur Urol 37 (2000) 306-313
5. Hartung R., Matzkin H., Alcaraz A., et al. Age, comorbidity, and hypertensive co-medication do not affect cardiovascular tolerability of 10 mg alfuzosin once daily. J Urol 175 (2006) 624-628
6. Berenyi P., Feher J., and Bognar F. The alpha-1-adrenoceptor blocker alfuzosin helps the spontaneous passage of distal ureteral stones [abstract]. Eur Urol Suppl 1 1 (2002) 34
7. Pricop C., Novac C., Negru D., Ilie C., Pricop A., and Tanase V. Can selective alpha-blockers help the spontaneous passage of the stones located in the uretero-bladder junction?. Rev Med Chir Soc Med Nat Iasi 108 (2004) 128-133
8. Basar M.M., Atan A., Ozergin O., and Yildiz M. The efficacy of alfuzosin treatment in patients with prostatism. Int Urol Nephrol 33 (2001) 493-497
9. Mehik A., Alas P., Nickel J.C., Sarpola A., and Helstrom J.P. Alfuzosin treatment for chronic prostatitis/chronic pain syndrome: a prospective, randomized, double-blind, placebo controlled pilot study. Urology 62 (2003) 425-429
10. Netea R.T., Lenders J.W., Smits P., and Thien T. Arm position is important for blood pressure measurement. J Hum Hypertens 13 (1999) 85-86
11. McKeage K., and Plosker L.G. Alfuzosin: a review of the therapeutic use of the prolonged release formulation given once daily in the management of benign prostatic hyperplasia. Drugs 62 (2002) 633-653
12. Lowe F.C., Olson P.J., and Padley R.J. Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications. Urology 54 (1999) 81-85
13. Roehrborn C.G., Van Kerrebroeck P., and Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double blind, placebo controlled studies. BJU Int 92 (2003) 257-261
14. Wolf-Mayer K., Cooper R.S., Banegas J.R., et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 289 (2003) 2363-2369
15. Rauch C., Ahtoy P., Pinquier J.L., et al. Bioequivalence of a new once a day controlled release alfuzosin formulation with the immediate release alfuzosin [abstract]. Eur Urol 37 (2000) 119
16. Rauch C., Andre F., and Thenot J.P. Bioequivalence of a new once a day controlled release alfuzosin formulation with the 5 mg twice daily formulation [abstract]. J Urol 16 (2000) 306
17. Nieminen T., Ylitalo R., Koobi T., Ylitalo P., and Kahonen M. The vasodilatory effect of alfuzosin and tamsulosin in passive orthostasis. A randomised, double blind, placebo-controlled study. Eur Urol 47 (2005) 340-345
18. Marks L.S., Roehrborn C.G., Gittelman M., Kim D., Forrest J., and Jacobs S. First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia. Urology 62 (2003) 888-893
19. Anagnostou T., and Tolley D. Management of ureteric stones. Eur Urol 45 (2004) 714-721
20. Dellabella M., Milanese G., and Muzzonigro G. Efficacy of tamsulosin in the medical management of juxtavesical ureteral stones. J Urol 170 (2003) 2202-2205
21. Porpiglia F., Vaccino D., Billia M., et al. Corticosteroids and tamsulosin in the medical expulsive therapy for symptomatic distal ureteral stones: single drug or association?. Eur Urol 50 (2006) 339-344
22. Schaeffer A.J. Epidemiology and demographics of prostatitis. Eur Urol Suppl 2 2 (2003) 5-10
23. Amato M., Lusini M.L., and Nelli F. Epidemiology of nephrolithiasis today. Urol Int 11 (2004) 1-5